Thymosin Beta-4

The full-length actin-binding peptide from which TB-500 is derived, studied for wound and corneal healing.

What research shows

Thymosin beta-4 is the full-length peptide from which TB-500 is derived, and it has more human evidence: randomized trials in corneal repair and a cardiac cell-therapy study. Its actin-binding role is well characterised. The injectable research market sells the fragment, not this.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.